Kyverna Therapeutics, Inc.

NasdaqGS:KYTX Stock Report

Market Cap: US$172.7m

Kyverna Therapeutics Past Earnings Performance

Past criteria checks 0/6

Kyverna Therapeutics's earnings have been declining at an average annual rate of -49.4%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 129.5% per year.

Key information

-49.4%

Earnings growth rate

51.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-129.5%
Return on equity-36.6%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Kyverna Therapeutics: CAR T-Cells Trying To Impact Inflammatory Disorders

Dec 12

Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation

Nov 17
Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation

We're Not Very Worried About Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Rate

Aug 08
We're Not Very Worried About Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Rate

Revenue & Expenses Breakdown

How Kyverna Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:KYTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-111240
31 Mar 240-76160
31 Dec 230-60120
30 Sep 230-48100
31 Dec 227-2980
31 Dec 216-2660

Quality Earnings: KYTX is currently unprofitable.

Growing Profit Margin: KYTX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if KYTX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare KYTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KYTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: KYTX has a negative Return on Equity (-36.55%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:46
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kyverna Therapeutics, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mitchell KapoorH.C. Wainwright & Co.
Lut Ming ChengJ.P. Morgan
Thomas SmithLeerink Partners LLC